Open Label, Multi-center Roll-over Study to Assess Long Term Safety in Patients Who Have Completed a Global Novartis or GSK Sponsored Dabrafenib and/or Trametinib Study
Phase of Trial: Phase IV
Latest Information Update: 04 Sep 2019
Price : $35 *
At a glance
- Drugs Dabrafenib (Primary) ; Dabrafenib (Primary) ; Trametinib (Primary) ; Trametinib (Primary)
- Indications Glioma; Malignant melanoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Novartis Pharmaceuticals
- 13 Jul 2018 Planned End Date changed from 9 Nov 2020 to 17 Jul 2023.
- 13 Jul 2018 Planned primary completion date changed from 9 Nov 2020 to 17 Jul 2023.
- 06 Feb 2018 Planned End Date changed from 16 Dec 2022 to 9 Nov 2020.